About this Talk

In this session we will discuss the current state of clinical trials in new-onset T1D reviewing lessons learned, the impact of new technologies such as CGMs and insulin-pumps, and the inherent challenges of conducting clinical trials in this space.

  • Topic One: What’s Been Done and What Does It Tell Us? 
  • Topic Two: The Impact of Technology on Conduct of Trials
  • Topic Three: Challenges of Conducting Trials in New-Onset T1D
  • Panel Discussion: Conduct of Clinical Trials in T1D

05:00 PM - 06:45 PM

About The Speakers

Matthias von Herrath

Matthias von Herrath

Vice President, Novo Nordisk


Tadej Battelino

Tadej Battelino

Profressor, University Medical Center Ljubljana


Joshua A. Vieth, PhD

Joshua A. Vieth, PhD

Senior Director, Research, Breakthrough T1D


Ulf Hannelius

Ulf Hannelius

President & CEO, Diamyd Medical


Carla Greenbaum

Carla Greenbaum

Director Center for Interventional Immunology, Benaroya Research Institute


Carmella Evans-Molina, MD, PhD

Carmella Evans-Molina, MD, PhD

Eli Lilly Professor of Pediatric Diabetes, Indiana University School of Medicine


Lauren Wood Heickman, MD

Lauren Wood Heickman, MD

Medical Officer, Division of Diabetes, Lipid Disorders, and Obesity, FDA


Laura Knecht, MD

Laura Knecht, MD

Group Principal Clinical Research Director, Sanofi

Moderators

Peter Gottlieb, MD

Peter Gottlieb, MD

Professor, University of Colorado, Anschutz Medical Campus